Proc. Natl. Acad. Sci. USA
Vol. 84, pp. 2117-2124, April 1987
Biochemistry
Cancer genes: Rare recombinants instead of activated oncogenes
(A Review)
(retroviral oncogenes/protooncogenes/illegitimate recombination/clonal chromosomal abnormalities)
PETER H. DUESBERG*
Department of Molecular Biology, University of California, Berkeley, Wendell M. Stanley Hall, Berkeley, CA 94720
Contributed by Peter H. Duesberg, December 22, 1986
ABSTRACT
The 20 known transforming (onc) genes of
retroviruses are defined by sequences that are transduced from
cellular genes termed protooncogenes or cellular oncogenes.
Based on these sequences, viral onc genes have been postulated
to be transduced cellular cancer genes, and proto-onc genes
have been postulated to be latent cancer genes that can be
activated from within the cell to cause virus-negative tumors.
The hypothesis is popular because it promises direct access to
cellular cancer genes. However, the existence of latent cancer
genes presents a paradox, since such genes are clearly undesirable. The hypothesis predicts (i) that viral onc genes and
proto-onc genes are isogenic; (it) that expression of proto-onc
genes induces tumors; (iii) that activated proto-onc genes
transform diploid cells upon transfection, like viral onc genes;
and (iv) that diploid tumors exist. As yet, none of these
predictions is confirmed. Instead: (i) Structural comparisons
between viral onc genes, essential retroviral genes, and protoonc genes show that all viral onc genes are indeed new genes,
rather than transduced cellular cancer genes. They are recombinants put together from truncated viral and truncated
proto-onc genes. (ii) Proto-onc genes are frequently expressed
in normal cells. (iii) To date, not one activated proto-onc gene
has been isolated that transforms diploid cells. (iv) Above all,
no diploid tumors with activated proto-onc genes have been
found. Moreover, the probability of spontaneous transformation in vivo is at least 109 times lower than predicted from the
mechanisms thought to activate proto-onc genes. Therefore,
the hypothesis that proto-onc genes are latent cellular oncogenes appears to be an overinterpretation of sequence homology to structural and functional homology with viral onc genes.
Here it is proposed that only rare truncations and illegitimate
recombinations that alter the germ-line configuration of cellular genes generate viral and possibly cellular cancer genes. The
clonal chromosome abnormalities that are consistently found in
tumor cells are microscopic evidence for rearrangements that
may generate cancer genes. The clonality indicates that the
tumors are initiated with, and possibly by, these abnormalities,
as predicted by Boveri in 1914.
In order to understand cancer, it is necessary to identify
cancer genes. The search for such genes and for mechanisms
that generate such genes must take into consideration that, at
the cellular level, cancer is a very rare event. The kind of
cellular transformation that leads to cancer in vivo occurs
only in about 1 out of 2 x 1017 mitoses in humans or animals.
The basis for this estimate is that most animal and human
cancers are derived from single transformed cells and hence
are monoclonal (1-4), that humans and corresponding animals represent about 1016 mitoses (assuming 1014 cells that go
through an average 102 mitoses), and that about one in five
persons dies from cancer (5).
The only proven cancer genes are the transforming (onc)
genes of retroviruses. These are autonomous transforming
genes that are sufficient for carcinogenesis (6, 7). They
transform susceptible cells in culture or in animals with the
same kinetics as they infect them (6, 7). Therefore, these
viruses are never associated with healthy animals and are by
far the most direct and efficient natural carcinogens.
However, tumors with retroviruses that contain onc genes
are very rare in nature; less than 50 cases are recorded from
which such viruses were isolated (4, 6-8). Moreover, these
viruses never have been reported to cause epidemics of
cancer. The probable reasons are that viral onc genes arise
naturally only with great difficulty, via two or more illegitimate recombinations, and that once arisen they are very
unstable because they are not essential for virus replication
(6, 7). Nonessential genes are readily lost due to spontaneous
deletion or mutation. Indeed, onc genes were discovered by
analysis of spontaneous deletions of the src gene, the onc
gene of Rous sarcoma virus (RSV) (9, 10). Subsequently,
about 20 other viral onc genes were identified in retroviruses
(6, 7, 8, 11). All of these viral onc genes were originally
defined by "transformation-specific" sequences that are
different from the known sequences of essential virus genes
(12).
Since onc genes are unstable, they must also be recent
additions to retroviruses. Indeed, the cellular genes from
which the transformation-specific sequences of oncogenic
retroviruses were transduced have been identified in normal
cells. This was done initially by liquid hybridization of
transformation-specific viral sequences with cellular DNA
(13-17) and later by comparing cloned viral onc and corresponding cellular genes (18). The cellular genes from which
viral onc sequences are derived have since been termed
proto-onc genes (6).
The cellular origin of the transformation-specific sequences of retroviral onc genes is frequently presented as a
particular surprise (8, 11). However, cells are the only known
source of genetic material from which viruses could
transduce genetic information, and viral transduction has
been canonical knowledge ever since phage X was first shown
to transduce 1-galactosidase in the 1950s. Indeed, viruses are
themselves derivatives of cellular genes that have evolved
away from their progenitor genes as they acquired their
capacity of self-replication.
The Hypothesis That Proto-onc Genes Are Latent Cancer
Genes. On the basis of the sequence homology between viral
onc genes and proto-onc genes, viral onc genes have been
postulated to be transduced cellular cancer genes, and
proto-onc genes have been postulated to be latent cancer
genes or oncogenes (19-27, 103). According to this view,
termed the oncogene concept (27), proto-onc genes are not
only converted to transforming genes from without by transducing viruses but also converted from within the cell by
increased dosage or increased function (19-27, 103). Activation of latent oncogenes from within the cell is postulated to
Abbreviation: RSV, Rous sarcoma virus.
*Present address: Fogarty Scholar-in-Residence, John E. Fogarty
International Center, National Institutes of Health, Bldg. 16,
Bethesda, MD 20892
2117
2118
Biochemistry: Duesberg
follow one of five prominent pathways: (i) point mutation (28,
29), (ii) chromosomal translocation that brings the latent
oncogene under the control of a heterologous enhancer or
promoter (23, 30), (iii) gene amplification (26, 27), (iv)
activation from a retroviral promoter integrated adjacent to
the latent oncogene (8, 22-27), or (v) inactivation of a
constitutive suppressor (31). Thus, this view predicts that
latent cancer genes exist in normal cells. However, the
existence of latent cancer genes is a paradox, because such
genes would obviously be undesirable for eukaryotic cells.
The oncogene concept was a revision of Huebner's oncogene hypothesis, which postulated activation of latent oncogenic viruses instead of latent cellular oncogenes as causes of
cancer (32). Nevertheless, Huebner's hypothesis remained
unconfirmed because most human and animal tumors are
virus-negative (8, 11). Moreover, the retroviruses and DNA
viruses that have been isolated from tumors are not directly
oncogenic (4), except for the less than 50 isolates of animal
retroviruses that contain onc genes (7, 8, 11).
The revised oncogene hypothesis was at first sight highly
attractive because it derived credibility from the proven
oncogenic function of retroviral onc genes, the viral derivatives of proto-onc genes, and because it promised direct
access to the long-sought cellular cancer genes in virus-free
tumors by use of previously defined viral onc genes as
hybridization probes. Predictably, the hypothesis has focused the search for cellular cancer genes among the 106
genes of eukaryotic cells on the 20 known proto-onc genes (7,
8, 23-27).
The hypothesis makes four testable predictions: (i) that
viral onc genes and proto-onc genes are isogenic; (ii) that
expression of proto-onc genes would cause cancer; (iii) that
proto-onc genes from tumors would transform diploid cells as
do proviral DNAs of viral onc genes, and, above all, (iv) that
diploid tumors exist that differ from normal cells orily in
activated proto-onc genes. Despite record efforts in the last
6 years, none of these predictions has been confirmed.
Instead: (i) Genetic and biochemical analyses that have
defined essential retroviral genes, viral onc genes, and
proto-onc genes during the last 16 years showed that viral onc
genes and proto-onc genes are not isogenic (6, 7) (see below).
(ii) Further, it turned out that most proto-onc genes are
frequently expressed in normal cells (7). (iii) Contrary to
expectation, none of the 20 known proto-onc genes isolated
from tumors functions as a transforming gene when introduced into diploid cells. The apparent exceptions of proto-ras
and proto-myc are discussed below. By comparison, proviral
DNAs of retroviral onc genes transform normal cells exactly
like the corresponding viruses (8, 11). (iv) As yet, no diploid
tumors with activated proto-onc genes have been found,
except for those caused by viruses with onc genes (33, 34).
Instead of activated oncogenes (7), clonal chromosome
abnormalities are a consistent feature of virus-negative tumors (1-3, 35) and also of all those tumors that are infected
by retroviruses without onc genes (4).
The Claim That Proto-ras Genes Become Cancer Genes Due
To Point Mutations. Harvey proto-ras is the cellular precursor of the ras genes of Harvey, BALB, and Rasheed murine
sarcoma viruses, and Kirsten proto-ras is the cellular precursor of the ras gene of Kirsten murine sarcoma virus (8, 11).
Both proto-ras and the viruses encode a colinear protein,
termed p21, of 189 amino acids (Fig. 1). In 1982 it was
discovered that Harvey proto-ras extracted from a human
bladder carcinoma cell line, but not from normal cells, would
transform the morphology of a few aneuploid murine cell
lines, in particular the 3T3 mouse cell line (28, 29). Subsequently, proto-ras DNAs from some other cell lines and from
some primary tumors were also found to transform 3T3 cells
(7, 43-45). Since such proto-ras genes behave like dominant
and autonomous cancer genes in this morphological assay,
Proc. Natl. Acad. Sci. USA 84 (1987)
they were claimed to be cellular cancer genes (8, 28, 29). The
3T3 cell-transforming function of the Harvey proto-ras gene
from the bladder carcinoma was reduced to a single point
mutation that changed the 12th ras codon of p21 from the
normal glycine to valine (28, 29). In the meantime, more than
50 different point mutations in five different ras codons have
been identified that all activate 3T3 cell-transforming function (39, 46). Since the viral ras genes and proto-ras genes
encode the same p21 proteins, whereas most other viral onc
genes encode proteins that are different from those encoded
by proto-onc genes (Fig. 1; refs. 6 and 7), this system has been
considered a direct support for the hypothesis that viral onc
genes and proto-onc genes are indeed isogenic and hence can
become functionally equivalent by point mutations or enhanced expression (25-29, 46, 103).
However, the following arguments cast doubt on the claims
that point mutations are necessary or sufficient to convert
proto-ras to a dominant cancer gene.
(i) The observations that most, but not all (see below),
proto-ras genes with point mutations have been found in
tumors or in certain cell lines appear to support the proposal
that point mutations convert proto-ras genes to dominant
cancer genes. However, the case is significantly weakened
because, in most spontaneous tumors, ras mutations are very
rare (7, 43-45). In fact, the glycine-*valine mutation that was
originally found in the human bladder carcinoma cell line (28,
29) has never been found in a primary tumor. Even in certain
chemically induced or spontaneous tumors in which ras
mutations are relatively frequent, no consistent correlation
between ras mutations and tumors has been observed (7,
47-49).
Further, it is not known whether, in animals, the origin of
a ras mutation coincides with the origin of the tumor. For
example, the ras mutation of the human bladder carcinoma
(28, 29) was only found in a cell line 10 years after this line
was derived from the original tumor (50).
On the basis of a numerical argument it is also unlikely that
point mutations are sufficient to convert proto-ras genes to
dominant cancer genes. The frequency of point mutations of
eukaryotes is 1 in 108-1010 nucleotides per mitosis (51, 52).
Thus, about 1 in 107 mitoses is expected to generate mutant
Harvey ras genes with dominant transforming function, since
the diploid human cell contains about 6 x 109 nucleotides and
since 50 different mutations can activate each of two sets of
ras genes of diploid cells. By contrast, spontaneous transformation that leads to clonal tumors occurs in less than 1 out
of about 2 x 1017 mitoses, and only a small minority of the
resulting cells contain mutant ras genes.
It may be argued that indeed 1 out of 107 mitoses generates
a tumor cell with activated proto-ras but that the immune
system eliminates most of these cells. However, this is
unlikely, since a point mutation is not an easy target for
immunity. Further, animals or humans that are tolerant to ras
point mutations would be expected to develop tumors at a
very early age, if point-mutated proto-ras genes were dominant cancer genes as the 3T3 assay suggests. Instead,
spontaneous human tumors with activated proto-ras are very
rare and all were observed in adults (7, 43-45). Moreover, the
argument that cellular oncogenes exist that can be activated
by point mutation and then controlled by immunity is hard to
reconcile with the existence of athymic or nude mice, which
do not develop more spontaneous tumors than other laboratory mice (53). Furthermore, this view is inconsistent with the
evidence that immunosuppressive therapy or thymectomy
does not increase the cancer rate of humans (54). Finally, one
would predict that in the absence of immunity, as in cell
culture, 1 out of 107 normal cells should spontaneously
transform due to point mutation of Harvey proto-ras alone,
and probably the same number due to mutation of Kirsten
Biochemistry: Duesberg
proto-ras (8). Yet spontaneous transformation of diploid cells
in culture is clearly a much less frequent event.
In an effort to directly test the hypothesis that ras genes are
activated to dominant cancer genes by point mutation, we
(39) analyzed whether the transforming function of ras genes
does indeed depend on point mutations. Using site-directed
mutagenesis, we found that point mutations are not necessary
for transforming function of viral ras genes and proto-ras
genes that have been truncated to be structurally equivalent
to viral ras genes (39).
(ii) Contrary to expectation, the same proto-ras DNAs
from human tumors that transform aneuploid 3T3 cells do not
transform diploid human (55) or diploid rodent (56-58) cells,
the starting material of natural tumors. Thus, transformation
of 3T3 cells does not appear to be a reliable assay for
transforming genes of diploid cells. Instead of initiating
malignant transformation, mutated proto-ras genes just alter
the morphology and enhance the tumorigenicity of aneuploid
3T3 cells. Apparently, they activate one of the many morphogenic programs of eukaryotic cells. Observations that
untreated 3T3 cells are turnorigenic in nude mice (59-61) are
consistent with this view. Thus, proto-ras genes with point
mutations are not sufficient to initiate malignant transformation. They only appear as dominant cancer genes in certain
aneuploid cells like the 3T3 cells because of unknown
biochemical effects that alter the morphology of these cells.
Furthermore, morphological transformation of 3T3 cells is
not ras gene-specific. It occurs spontaneously (62) and also
upon transfection with other DNA species derived from
tumors or tumor cell lines that, like proto-ras, do not
transform diploid cells (26, 47, 48). Such DNAs are now
widely considered as cellular cancer genes (26, 47, 48),
although they are not related to viral onc genes and do not
transform diploid cells.
(iii) Assuming that mutated proto-ras genes are cancer
genes like viral onc genes, one would expect diploid tumors
that differ from normal cells only in ras point mutation.
Contrary to expectation, chromosome abnormalities are
consistently found in those tumors in which proto-ras mutations are occasionally found (1, 3). The human bladder
carcinoma cell line in which the first proto-ras mutation was
identified is a convincing example. This cell line contains
more than 80 chromosomes instead of 46 and includes
rearranged marker chromosomes (50). In view of such
fundamental chromosome alterations, a point mutation
seems to be a rather minor event. Indeed, among diploid
hamster cells transfected with mutated ras genes, only those
that developed chromosomal abnormalities upon transfec-
tion were tumorigenic (63).
Thus, proto-ras genes with point mutations are neither
sufficient nor proven to be necessary for carcinogenesis and
are not autonomous cancer genes like viral ras genes. In
addition, there is no kinetic evidence that the origin of the
mutation coincides with the origin of the tumors in which it
is found. It is consistent with this view that proto-ras
mutations that register in the 3T3 cell transformation assay
have been observed to occur in vivo in benign hyperplasias,
as for example in benign murine hepatomas (64) or in benign,
purely diploid mouse skin papillomas that differentiate into
normal skin cells (65-69). ras mutations have also been
observed to arise after carcinogenesis in aneuploid cancer
cells (70-72), rather than to coincide with the origin of cancer.
By contrast, viral ras genes are sufficient for transformation
and thus initiate transformation of diploid cells in vitro and in
vivo with single-hit kinetics and concurrent with infection (7,
73, 74).
This then raises the question why viral ras genes are
inevitably carcinogenic under conditions where proto-ras
genes with point mutations are not. A sequence comparison
between proto-ras genes and the known viral ras genes has
Proc. Natl. Acad. Sci. USA 84 (1987)
2119
recently revealed a proto-ras-specific exon that was not
transduced by any of the known retroviruses with ras genes
(39). It is not clear whether the untransduced exon has a
regulatory or a coding function (39). It follows, however, that
proto-ras and viral ras genes are not isogenic (Fig. 1). Since
four different viral ras genes have been shown to lack the
same proto-ras exon, and since point mutations are not
necessary for transforming function, we have proposed that
proto-ras genes derive transforming function for diploid cells
by truncation of an upstream exon and recombination with a
retroviral promoter (ref. 39, see below).
The Claim That the Proto-myc Gene Becomes a Cancer Gene
Under the Influence of a Heterologous Cellular Enhancer.
Proto-myc is the cellular precursor of the directly oncogenic
myc genes of four avian carcinoma viruses (MC29, MH2,
CMII, and 0K10) (7). The transforming host range of viral
myc genes appears to be limited to avian cells, as murine cells
are not transformed by cloned proviral DNAs (56, 57, 75).
Nevertheless, it is thought that proto-myc, brought under the
control of heterologous cellular enhancers or promoters by
chromosome translocation, is the cause of human Burkitt
lymphoma or mouse plasmacytoma (30, 67, 76).
The following arguments cast doubt on whether such
activated proto-myc genes are indeed necessary or sufficient
for carcinogenesis.
(i) The human proto-myc gene is located on chromosome
8. This chromosome is typically rearranged in B-cell lines
derived from Burkitt lymphomas (7, 30, 67). However,
although chromosome 8 is subjected to translocations, protomyc is frequently not translocated, and when translocated it
is frequently not rearranged (7, 30, 67). Moreover, no
rearrangements of chromosome 8 were observed in about
50% of primary Burkitt lymphomas; instead, other chromosome abnormalities were recorded (77). Thus, proto-myc
translocation is not necessary for lymphomagenesis.
(ii) Expression of proto-myc is not consistently enhanced
in lymphomas (7).
(iii) No proto-myc gene isolated from any tumor has been
shown to transform any cells (7). In an effort to assay
transforming function in vivo, a proto-myc gene that was
artificially linked to heterologous enhancers was introduced
into the germ line of mice (76). Several of these transgenic
mice developed lymphomas after 1-5 months, implying that
activated proto-myc had transformed diploid cells. However,
the lymphomas of the transgenic mice were all monoclonal
(76). Thus, if the activated proto-myc gene were indeed
responsible for the lymphomas, it would be an extremely
inefficient carcinogen, because only 1 of about 108 "control"
B cells of the same mouse (78) with the same transgenic myc
gene was transformed. There is no deletion or mutation
analysis to show that the activated proto-myc indeed played
a direct role in the tumors of the transgenic mice (76). In
contrast, viral myc genes transform all susceptible cells
directly and inevitably (7).
(iv) If translocated proto-myc were the cause of Burkitt
lymphomas, one would expect all tumors to be diploid and to
carry only two abnormal chromosomes-namely, number 8
and the chromosome that was subject to reciprocal translocation with number 8. Instead, primary Burkitt lymphomas
exist with two normal chromosomes 8 that carry other
chromosome abnormalities (77). Thus, translocated protomyc genes are neither sufficient nor proven to be necessary
for carcinogenesis.
The Probability of Spontaneous Transformation in Vivo Is At
Least 109 Times Lower Than Predicted from Proto-onc Gene
Activation. It was estimated above that the probability of
spontaneous transformation that leads to monoclonal tumors
in humans is 2 X 10-17 per mitosis. One would expect
activation of a preexisting, latent proto-onc gene to be a much
more frequent event. For a given proto-onc gene, the prob-
2120
Biochemistry: Duesberg
ability of activation per mitosis would be the sum of the
probabilities associated with each of the five putative pathways (26, 27, 31) of proto-onc activation. (i) Since the
probability of a point mutation per nucleotide per mitosis is
-10-9 (51, 52), the probability that any one of the 20 known
proto-onc genes is activated would be 2 x 20 x 10-9,
assuming only one activating mutation per proto-onc gene.
However, it would be 10-7 for Harvey ras alone, since 50
different mutations are thought to activate this gene to a
dominant cancer gene (see above).
(ii) The probability of a given proto-onc gene to be
activated by amplification is 10-8, considering that about 1
in 103-10W mitoses leads to gene amplification in vitro (and
possibly in vivo) and that about 103 out of the 106 kilobases
(kb) of eukaryotic DNA are amplified (79, 80). The probability that any one of the 20 known proto-onc genes would be
activated by amplification would then be 2 x 10-7.
(iii) The probability of oncogene activation by chromosome translocation depends largely on what the distance is
between a proto-onc gene and a heterologous enhancer, and
on which enhancers are considered sufficient for activation.
Since distances >50 kb of DNA have been considered
sufficient for activation of proto-myc (8, 67) and proto-abl (8,
81), the proto-onc gene of murine Abelson leukemia virus (8),
and since an enhancer is likely to be found in every 50 kb of
cell DNA, nearly every translocation within 50 kb of a
proto-onc gene should be activating. Thus the probability that
a given proto-onc gene is activated per translocation would
be 5 x 10-5 (50 kb out of 106 kb). The probability that one of
the 20 known proto-onc genes is activated would then be 10-3
per translocation.
Translocation frequencies per mitosis are not readily
available. In hamster cells, translocations are estimated to
occur with a probability of 10-6 per mitosis (82, 83). In cells
directly derived from mice and humans, even higher frequencies (0.01-0.3) have been observed upon study in vitro
(84-86). The probability of a translocation per meiotic cell
division in humans has been determined to be 10-3-10-4,
based on chromosome abnormalities in live births (87).
Assuming one translocation in 104 mitoses, the probability
that 1 out of the 20 known proto-onc genes is activated per
mitosis by translocation would then be about 10-7.
(iv) The probability that a proto-onc gene would be activated from without by the promoter or enhancer of a
retrovirus integrated nearby is even higher than those associated with the intrinsic mechanisms. Since retrovirus integration within 1-10 kb of a putative latent cancer gene is
considered sufficient for activation (8, 22-26), and since
retrovirus integration is not site-specific (8, 11) and eukaryotes contain about 106 kb of DNA, a given proto-onc gene
would be activated in at least 1 out of 106 infected cells (4, 7).
The probability that any one of the 20 known proto-onc genes
would be activated would be 2 x 10-5 per infected cell.
The sum of these probabilities should reflect the spontaneous transformation frequency of cells per mitosis in vivo
and in vitro. It would be between lo-5 and 10-. It should be
at least 10-7 due to Harvey proto-ras mutations alone.
Nevertheless, the actual number may be 10 times lower, or
about 10-8, depending on whether all or only some of these
four putative mechanisms could activate a proto-onc gene
and depending on whether a given cell is susceptible to
transformation by a given onc gene or to a given retrovirus.
Instead, spontaneous transformation per mitosis that leads to
monoclonal tumors is only about 2 x 10-17 in vivo. Thus, the
expected probability of spontaneous transformation due to
activation of preexisting oncogenes differs at least by a factor
of 109 from that observed in diploid cells in vivo.
Again, it may be argued that spontaneous malignant
transformation does indeed occur at the above rates but that
immunity eliminates nearly all transformants. However, in
Proc. Natl. Acad. Sci. USA 84 (1987)
this case athymic or nude mice should not exist and the
cancer incidence should increase significantly upon immunosuppressive therapy or thymectomy, yet this is not the
case (53, 54). Moreover, diploid cells in culture have not been
observed to transform at the above rates.
(v) Certain cancers (e.g., retinoblastomas) are thought to
be caused by activation of oncogenes that are normally
suppressed by two allelic suppressor genes (31). Cancers
caused by such genes would be the product of inactivations
of two allelic suppressors and thus very rare (31). In individuals with genetic defects in one putative suppressor allele,
tumors such as retinoblastomas possibly occur due to inactivation of the second suppressor allele with frequencies
similar to those estimated above for point mutation, translocation, and retrovirus insertion (31).
However, in more than 80% of retinoblastomas that occur
in individuals without prior genetic defect, the putative
suppressor genes appear to be normal as judged by chromosome analysis (31), arguing either that other suppressors
inhibit the putative retinoblastoma oncogene or that it does
not exist. Instead, other chromosomal abnormalities that are
always seen in such tumors (31) may be relevant to
carcinogenesis (see below). Further, this activation hypothesis predicts that normal cellular DNA would cure
retinoblastoma cells upon experimental transfection, yet this
has not been reported. Likewise, it would be expected that
experimental, human-nonhuman heterokaryons that lack
chromosomes with suppressor genes would be transformed,
but this has also not been reported. Thus there is as yet no
proof for suppressed cancer genes in normal cells.
The Hypothesis That Activated Proto-onc Genes Require
Unknown Complementary Genes for Carcinogenesis. Because
of the consistent difficulties in demonstrating oncogenic
function of proto-onc genes, a revision of the oncogene
concept has recently been favored. It proposes that "activated" proto-onc genes, like proto-ras or proto-myc, are not
autonomous onc genes like their viral derivatives but are at
least necessary for the kind of carcinogenesis that requires
multiple cooperating oncogenes (30, 57, 67, 68, 88, 89). Thus,
activated proto-onc genes are proposed to be functionally
different from, yet structurally equivalent to, viral onc genes.
According to this theory, activated proto-onc genes would
not be expected to register in transformation assays that
detect single-hit carcinogens like viral onc genes (6, 7).
However, this hypothesis fails to provide even a speculative explanation for why activated proto-onc genes are no
longer to be considered functionally equivalent to viral onc
genes (7). Clearly, until the postulated complementary cancer
genes are identified, this hypothesis remains unproven (7).
The hypothesis also fails to explain why among certain
tumors, such as the human carcinomas, individual carcinomas are only distinguishable from each other by the presence
or absence of activated, putative oncogenes (7, 43-45). This
implies either (a) that unknown oncogenes that do not
register in the 3T3 cell assay would cause the same tumors as
the putative oncogenes that do or (b) that the putative
oncogenes are not necessary for these tumors.
Viral onc Genes as Specific Recombinants Between Truncated Viral and Cellular Genes. Genetic and structural analyses of retroviral genes, viral onc genes, and proto-onc genes
and direct comparisons between them have shown that viral
onc genes and proto-onc genes are different both structurally
and functionally. Therefore, it has been proposed that viral
onc genes are indeed new genes that do not preexist in normal
cells, rather than being transduced cellular genes (refs. 6, 7,
12, and 18; Fig. 1). The original basis for this proposal was the
definition of the transforming gene of avian carcinoma virus
MC29 (90) as a genetic hybrid rather than a transduced
cellular oncogene (37). It consists of 5' regulatory and coding
elements (Agag) from an avian retrovirus linked to 3' coding
Proc. Natl. Acad. Sci. USA 84 (1987)
Biochemistry: Duesberg
proto-onc genes
5'??
S
DZ
=
Retrovirus
8 to 9 kb
FIG. 1. The generic, recombinant structures of retroviral onc
and their relationship to viral onc genes (stippled) and cellular
proto-onc genes (unshaded). The genes are compared as transcriptional units or mRNAs. All known viral onc genes are tripartite
hybrids of a central sequence derived from a cellular proto-onc gene,
which is flanked by 5' and 3' elements derived from retroviral
"fproto-onc" genes. Actual size differences, ranging from >1 to 7
kilobases (kb) (8), are not recorded. The map order of the three
essential retrovirus genes, gag, pol, and env, and the splice donor
(SD) are indicated. Four groups of viral onc genes are distinguished
based on the origins of their coding sequence (C:ID). (Group 1)
The coding unit has a tripartite structure of a central proto-oncderived sequence that is initiated and terminated by viral coding
sequences. Avian myeloblastosis virus (AMV) is an example (8, 36).
(Group 2) The coding unit is initiated by a viral sequence and
terminated by a proto-onc sequence. The Agag-myc gene of avian
carcinoma virus MC29 is an example (7, 8, 18, 37). The hybrid onc
genes of Fujinami avian sarcoma virus (FSV) (38) and Abelson
murine leukemia virus (AbLV) are other examples (8). (Group 3) The
coding unit of the viral onc gene is colinear with a reading frame of
a cellular proto-onc gene. The ras gene of the Harvey and BALB
murine sarcoma viruses (HaSV and BaSV) (39) and the myc gene of
the avian carcinoma virus MH2 are examples (40, 41). (Group 4) The
coding unit is initiated by a proto-onc-derived domain and terminated
by a viral reading frame. The src gene of Rous sarcoma virus (RSV)
is an example (6, 8). The transcriptional starts and 5' nontranscribed
regulatory sequences (?) of all proto-onc genes are as yet not, or not
exactly, known (7, 8). There is also uncertainty about 5' translational
starts and open reading frames in some proto-onc genes (?) that are
not transduced into viral onc genes, as in proto-myc (42), proto-src
(6), or proto-ras (39). It is clear, however, that proto-onc-specific
regulatory elements are always replaced by viral promoters and
enhancers and that proto-onc coding sequences are frequently
recombined with viral coding sequences. Thus, all viral onc genes are
tripartite recombinant genes of truncated viral and proto-onc genes.
genes
elements from cellular proto-myc (ref. 37; Fig. 1). Initially
this became evident from comparison of the structure and
map order of MC29 with that of the three essential retrovirus
genes, 5'gag-pol-env 3' (refs. 91 and 92; Fig. 1).
Sequence comparison of the viral Agag-myc gene with the
chicken proto-myc gene provided direct proof that only a
truncated proto-myc gene was present in MC29. Indeed, a
complete 5' proto-myc exon was missing from the viral
Agag-myc gene (18). This was apparently not an accident,
since the same 5' proto-myc exon was also missing in the
three other myc-containing avian carcinoma viruses MH2
(40, 41), CMII, and OK10 (7, 93). Thus, a viral and a cellular
gene functioned as progenitors or proto-onc genes of each of
the viral recombinant myc genes (Fig. 1). More recently, the
four known viral ras genes were each also shown to lack a 5'
proto-ras exon (ref. 39; see above; Fig. 1).
2121
Comparisons between the onc genes of other retroviruses
and the corresponding proto-onc genes proved that all viral
onc genes, defined as transcriptional units, are new genes
that are recombinants of proto-onc genes and retroviral genes
(refs. 6-8; Fig. 1). Most but not all viral genes also encode
new recombinant proteins. Based on the origin of their coding
elements, the viral onc genes can be divided into four groups
(Fig. 1). Group I includes those with amino- and carboxylterminal domains from retroviruses and central domains from
proto-onc genes. The onc gene of avian myeloblastosis virus
is the prototype (8, 36). Group 2 includes those with aminoterminal domains from viral genes and carboxyl-terminal
domains from proto-onc genes. The Agag-myc gene of MC29
is the original example (see above). The onc genes of
Fujinami sarcoma virus (38) and Abelson leukemia virus (8)
also have the generic Agag-X structure. Group 3 includes
those that are colinear with a reading frame of a proto-onc
gene. The ras genes of Harvey and BALB murine sarcoma
virus (39) and the myc gene of avian carcinoma virus MH2
(40, 41) are examples. Group 4 includes those with an
amino-terminal domain from a proto-onc gene and a
carboxyl-terminal domain from the virus. The src gene of
RSV is the prototype (6, 8).
Since three of the four groups of recombinant viral onc
genes also encode recombinant proteins, their specific transforming function can be directly related to their specific
structure compared to that of proto-onc gene products. The
transforming function of the recombinant onc genes of group
3, which encode transforming proteins that are colinear with
proteins encoded by proto-onc genes, cannot be explained in
this fashion. However, all viral onc genes of this group each
lack at least one proto-onc-specific 5' exon, like the avian
carcinoma viruses with myc genes (7, 18, 40, 41, 93) or the
murine sarcoma viruses with ras genes (39). Conceivably,
elimination of transcribed or untranscribed suppressors or
elimination of an upstream proto-ras cistron (39) or protomyc cistron (42) and recombination with viral promoters are
the mechanisms that generate transforming function (Fig. 1).
It follows that viral onc genes and the corresponding
proto-onc genes are not isogenic. Viral onc genes are hybrid
genes that consist of truncated proto-onc genes recombined
with regulatory and, frequently, with coding elements from
truncated retroviral genes. These consistent structural differences must be the reason why viral onc genes inevitably
transform and why proto-onc genes are not transforming
although they are present in all and are active in most normal
cells (6, 7).
Clearly, if cellular oncogenes preexist in normal cells, it
would be much more likely to find retroviruses with intact
cellular oncogenes than retroviruses with new onc genes put
together from unrelated and truncated viral and cellular genes
by illegitimate recombination. However, it may be argued
that proto-onc gene truncations reflect packaging restrictions
of transducing retroviruses, rather than conditions to activate
proto-onc genes. Such restrictions would have to be mostly
sequence-specific, as most retroviruses with onc genes can
accommodate more RNA [at least 10 kb as in RSV (94)] than
they actually contain [3-8 kb (8)]. But there is no evidence
that retroviruses discriminate more against certain transduced or artificially introduced sequences (8) than against
others, because retroviruses can accommodate very heterogenous sequences, such as the 20 different transformationspecific sequences (6, 7, 8, 12). Yet all nonessential sequences of retroviruses are unstable and hence lost unless
selected for a given function (6, 7).
Moreover, the fact that the same exons were selectively
truncated from proto-onc genes in independent viral transductions that have generated active onc genes indicates that
specific truncations are necessary for transforming functions.
Examples are selective truncations of proto-myc, the precur-
2122
Biochemistry: Duesberg
sor of four avian carcinoma viruses (7, 18, 40); proto-ras, the
precursor of three murine sarcoma viruses (39); proto-myb,
the precursor of avian myeloblastosis and erythroblastosis
viruses (8, 95); proto-erb, the precursor of three avian
sarcoma and erythroblastosis viruses (8); proto-fes, the
precursor of three feline sarcoma viruses (8); proto-fps, the
precursor of three avian sarcoma viruses (8, 96); proto-abl,
the precursor of Abelson murine leukemia virus and a feline
sarcoma virus (8); proto-mos, the precursor of several
Moloney sarcoma viruses (8, 97); and proto-src, the precursor of RSV and two other avian sarcoma viruses (98). In some
cases of such selective transductions, the same exons were
even truncated at exactly the same breakpoints, as for
example in two different avian sarcoma viruses derived from
proto-fps (96).
The existence of at least five retroviruses containing
proto-onc sequences that had already been truncated by
recombination with other cellular genes prior to transduction
lends further independent support to this view. Examples are
the onc genes of avian carcinoma virus MH2 (7, 40, 41), of
avian erythroblastosis and sarcoma virus AEV (8), of avian
erythro- and myeloblastosis virus E26 (95), of feline sarcoma
virus GR-FeSV (8, 99), and of RSV (6, 8). Certainly the odds
against transduction of rare rearranged proto-onc genes
instead of normal proto-onc genes are overwhelming. Yet
five out of the less than 50 known isolates of retroviruses with
onc genes (8) contain previously rearranged proto-onc sequences, most likely because truncation is necessary for
transforming function. Indeed, it may be argued that these
viruses have transduced these rearranged proto-onc genes
from a preexisting tumor that was generated by these rearrangements. Thus, the rearranged proto-onc genes of these
five oncogenic retroviruses may be "transduced cellular
oncogenes" after all.
Therefore, truncation of proto-onc genes by recombination
with retroviral or cellular genes appears to be necessary to
convert proto-onc genes to transforming genes. A definitive
assessment of why viral onc genes transform, and cellular
proto-onc genes don't, requires more than comparisons of
primary structures and transforming tests with DNAs. It will
be necessary to know what proto-onc genes do and whether
they encode proteins that function alone or as complexes
with other proteins.
I propose, then, that proto-onc genes that are transcriptionally activated or have undergone point mutations, but
retain a germ-line structure, are not cellular cancer genes. I
suggest that the hypothesis that proto-onc genes are latent
cellular cancer genes that can be converted to active transforming genes, by increased dosage or function, is an
overinterpretation of sequence homology to structural and
functional homology with viral onc genes.
This proposal readily resolves the paradoxes posed by the
hypothesis that proto-onc genes are latent cellular cancer
genes that can be activated by enhanced expression or point
mutation. The proposal accounts for the frequent expression
of proto-onc genes in normal cells (7). The proposal is also
entirely consistent with the lack of transforming function of
"activated" proto-onc genes from tumors. The observation
that mutated proto-ras changes the morphology and enhances tumorigenicity of aneuploid and tumorigenic 3T3 cells
is important, but not an exception to the experience that
native proto-onc genes from tumors analyzed to date do not
transform diploid cells. The proposal also provides a rationale for the chromosome abnormalities of tumor cells, as
these appear to be microscopic evidence for cancer genes
(see below), instead of the "activated" proto-onc genes
identified to date.
The Hybrid onc Genes of Retroviruses as Models of Cellular
Cancer Genes. The proposal that proto-onc genes derive
transforming function by truncation and recombination with
Proc. Natl. Acad. Sci. USA 84 (1987)
retroviral or cellular genes predicts that recombinations
among cellular genes could also generate transforming genes.
The view that cellular cancer genes are rare recombinants of
normal cellular genes is in accord with the fact that rearranged and abnormal chromosomes are the only consistent,
transformation-specific markers of tumor cells (1-4, 35).
Further, the clonality of chromosome alterations [e.g., the
marker chromosomes of tumors (1-4, 35)] indicates that
tumors are initiated with, and possibly caused by, such
abnormalities, as originally proposed by Boveri in 1914 (100).
The generation of retroviral onc genes from viral genes and
proto-onc genes could indeed be a model for this process.
Less than 50 isolates of retroviruses with onc genes have
been documented (7, 8, 11), although both potential parents
of retroviral onc genes are available in many animal or human
cells because retroviruses are widespread in all vertebrates
(4, 8, 11). This extremely low birth rate of retroviruses with
onc genes must then reflect the low probability of generating
de novo an oncogenic retrovirus from a proto-onc gene and
a retrovirus by truncating and recombining viral and cellular
genes via illegitimate recombinations (6, 7, 12). Clearly, at
least two illegitimate recombinations are required (Fig. 1):
one to link a 3' truncated retrovirus with a 5' truncated
proto-onc gene, and the other to break and then splice the
resulting hybrid onc gene to the 3' part of the retroviral
vector.
The first of these steps would generate a "cellular" cancer
gene that ought to be sufficient for carcinogenesis. The birth
of such a gene would be more probable than that of an
oncogenic retrovirus that requires two illegitimate recombinations, but it would be harder to detect than a complete
replicating retrovirus with an onc gene. Nevertheless, even
this would be a rare event. Given that such a recombination
would have to take place within the 8-9 kb of a retrovirus
(Fig. 1) integrated into the 106-kb genome of a eukaryotic cell
and also within an estimated 1-2 kb of a proto-onc gene (Fig.
1), and assuming that translocation or rearrangement occurs
with a probability of lo-4, the probability of such a recombination per mitosis would be (8 x 10-6) x (2 X 10-6) X (lo-4)
10-'5. That a second illegitimate recombination is required
to generate a retrovirus with an onc gene would explain why
the occurrence of these viruses is much less frequent than
spontaneous transformation due to recombinant cancer
genes. This probability may, nevertheless, be higher than the
square of 10-15, since the two events may be linked and since
multiple integrated and unintegrated proviruses exist in most
infected cells.
The probability that illegitimate recombination would generate cancer genes from normal cellular genes would also be
very low, since most illegitimate recombination would inactivate genes. Inactivation of certain growth-control genes
may in fact be necessary for tumorigenesis. The above
estimates for the probability of spontaneous transformation
(2 x 10-17) per mitosis and of translocation (10-4), which
would be a minimal estimate for illegitimate recombination,
suggest that 10P translocations or rearrangements are needed
to generate a transforming gene that causes a monoclonal
tumor. This could be a single autonomous transforming gene
that is like a viral onc gene, or it could be a series of mutually
dependent transforming genes (101, 102) that would each
arise with a higher probability than an autonomous onc gene.
The facts that multiple chromosome alterations are typically
seen in tumors (1-3, 35, 77) and that as yet no DNAs have
been isolated from tumors that transform diploid cells with
single-hit kinetics suggest that most cellular cancer genes are
indeed not autonomous carcinogens like viral onc genes. It is
consistent with this view that most cellular genes are also not
converted to autonomous cancer genes by retroviral transduction via illegitimate recombination and truncation. Only
about 20 cellular genes, the proto-onc genes, have been
Biochemistry: Duesberg
converted to autonomous viral onc genes, although viral
transduction via illegitimate recombination is a random event
that does not benefit from sequence homology between
retroviruses and cells (6, 7, 12).
Thus, viral onc genes have not as yet fingered preexisting
cellular cancer genes. No cellular gene is a structural or
functional homolog of a viral onc gene, but the viral onc genes
appear to be models for how cancer genes may arise from
normal cellular genes by rare truncation and recombination.
I thank S. A. Aaronson, S. Blam, M. Kraus, M. Pech, K. Robbins,
S. Tronick and others from the Laboratory of Cellular and Molecular
Biology (National Cancer Institute, Bethesda, MD) for critical and
amusing discussions and generous support during a sabbatical leave
and B. Witkop (National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, Bethesda, MD) for asking many of the
basic questions that I try to answer in this manuscript. I also thank
my colleagues H. Rubin for encouragement and K. Cichutek, R.-P.
Zhou, D. Goodrich, S. Pfaff, and W. Phares (University of California, Berkeley, CA) for inspiring comments and their work. P.H.D. is
supported by National Cancer Institute Grant CA39915A-01 and
Council for Tobacco Research Grant 1547 and by a Scholarship-inResidence of the Fogarty International Center, National Institutes of
Health, Bethesda, MD.
1. Wolman, S. R. (1983) "Karyotypic progression in human tumors,"
Cancer Metastasis Rev. 2, 257-293.
2. Rowley, J. D. (1984) "Introduction: Consistent chromosomal alterations and oncogenes in human tumors," Cancer Surv. 3, 355-357.
3. Trent, J. M. (1984) "Chromosomal alterations in human solid tumors:
Implications of the stem cell model to cancer cytogenetics," Cancer
Surv. 3, 393-422.
4. Duesberg, P. H. (1987) "Retroviruses as carcinogens and pathogens:
Expectations and reality," Cancer Res. 47, 1199-1220.
5. Silverberg, E. & Lubera, J. (1986) "Cancer statistics," Ca-A Cancer J.
Clin. 36, 9-25.
6. Duesberg, P. H. (1983) "Retroviral transforming genes in normal
cells?" Nature (London) 304, 219-226.
7. Duesberg, P. H. (1985) "Activated proto-onc genes: Sufficient or
necessary for cancer?" Science 228, 669-677.
8. Weiss, R., Teich, N., Varmus, H. & Coffin, J., eds. (1985) RNA Tumor
Viruses: Molecular Biology of Tumor Viruses (Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY).
9. Duesberg, P. H. & Vogt, P. K. (1970) "Differences between the
ribonucleic acids of transforming and nontransforming avian tumor
viruses," Proc. NatI. Acad. Sci. USA 67, 1673-1680.
10. Martin, G. S. & Duesberg, P. H. (1972) "The a-subunit on the RNA of
transforming avian tumor viruses: (I) Occurrence in different virus
strains; (II) Spontaneous loss resulting in nontransforming variants,"
Virology 47, 494-497.
11. Weiss, R., Teich, N., Varmus, H. & Coffin, J., eds. (1982) RNA Tumor
Viruses: Molecular Biology of Tumor Viruses (Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY).
12. Duesberg, P. H. (1979) "Transforming genes of retroviruses," Cold
Spring Harbor Symp. Quant. Biol. 44, 13-27.
13. Scolnick, E. M., Rands, F., Williams, P. & Parks, W. P. (1973)
"Studies on the nucleic acid sequences of Kirsten sarcoma virus: A
model for formation of a mammalian RNA-containing sarcoma virus,"
J. Virol. 12, 458-463.
14. Scolnick, E. M. & Parks, W. P. (1974) "Harvey sarcoma virus: A
second murine type C sarcoma virus with rat genetic information," J.
Virol. 13, 1211-1219.
15. Tsuchida, N., Gilden, R. V. & Hatanaka, M. (1974) "Sarcoma-virusrelated RNA sequences in normal rat cells," Proc. Natl. Acad. Sci.
USA 71, 4503-4507.
16. Frankel, A. E. & Fischinger, P. J. (1976) "Nucleotide sequences in
mouse DNA and RNA specific for Moloney sarcoma virus," Proc.
Natl. Acad. Sci. USA 73, 3705-3709.
17. Stehelin, D., Varmus, H. E., Bishop, J. M. & Vogt, P. K. (1976)
"DNA related to the transforming gene(s) of avian sarcoma viruses is
present in normal avian DNA," Nature (London) 260, 170-173.
18. Watson, D. K., Reddy, E. P., Duesberg, P. H. & Papas, T. S. (1983)
"Nucleotide sequence analysis of the chicken c-myc gene reveals
homologous and unique regions by comparison with the transforming
gene of avian myelocytomatosis virus MC29, Agag-myc," Proc. Natl.
Acad. Sci. USA 80, 2146-2150.
19. Bishop, J. M., Courtneidge, S. A., Levinson, A. D., Oppermann, H.,
Quintrell, N., Sheiness, D. K., Weiss, S. R. & Varmus, H. E. (1979)
"Origin and function of avian retrovirus transforming genes," Cold
Spring Harbor Symp. Quant. Biol. 44, 919-930.
20. Karess, R. E., Hayward, W. S. & Hanafusa, H. (1979) "Transforming
protein encoded by the cellular information of recovered avian sarcoma
Proc. Natl. Acad. Sci. USA 84 (1987)
2123
viruses," Cold Spring Harbor Symp. Quant. Biol. 44, 765-771.
21. Wang, L.-H., Snyder, P., Hanafusa, T., Moscovici, C. & Hanafusa, H.
(1979) "Comparative analysis of cellular and viral sequences related to
sarcomagenic cell transformation," Cold Spring Harbor Symp. Quant.
Biol. 44, 755-764.
22. Bishop, J. M. (1981) "Enemies within: The genesis of retrovirus
oncogenes," Cell 23, 5-6.
23. Klein, G. (1981) "The role of gene dosage and genetic transposition in
carcinogenesis," Nature (London) 294, 313-318.
24. Bishop, J. M. & Varmus, H. (1982) "Functions and origins of retroviral
transforming genes in RNA tumor viruses," in RNA Tumor Viruses:
Molecular Biology of Tumor Viruses, eds. Weiss, R., Teich, N.,
Varmus, H. & Coffin, J. (Cold Spring Harbor Laboratory, Cold Spring
Harbor, NY), pp. 999-1108.
25. Bishop, J. M. (1983) "Cellular oncogenes and retroviruses," Annu.
Rev. Biochem. 52, 301-354.
26. Varmus, H. & Bishop, J. M. (1986) "Introduction: Biochemical mechanisms of oncogene activity: Proteins encoded by oncogenes," Cancer
Surv. 5, 153-158.
27. Weiss, R. A. (1986) "The oncogene concept," Cancer Rev. 2, 1-17.
28. Tabin, C. J., Bradley, S. M., Bargmann, C. I., Weinberg, R. A.,
Papageorge, A. G., Scolnick, E. M., Dhar, R., Lowy, D. R. & Chang,
E. H. (1982) "Mechanism of activation of a human oncogene," Nature
(London) 300, 143-149.
29. Reddy, E. P., Reynolds, R. K., Santos, E. & Barbacid, M. (1982) "A
point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene," Nature (London) 300, 149-152.
30. Leder, P., Battey, J., Lenoir, G., Moulding, C., Murphy, W., Potter,
M., Stewart, T. & Taub, R. (1983) "Translocations among antibody
genes in human cancer," Science 227, 765-771.
31. Knudson, A. G., Jr. (1985) "Hereditary cancer, oncogenes, and
antioncogenes," Cancer Res. 45, 1437-1443.
32. Huebner, R. J. & Todaro, G. (1969) "Oncogenes of RNA tumor viruses
as determinants of cancer," Proc. Natl. Acad. Sci. USA 64, 1087-1094.
33. Pitot, H. C. (1978) Fundamentals of Oncology (Dekker, New York).
34. Klein, G., Ohno, S., Rosenberg, N., Wiener, F., Spira, J. & Baltimore,
D. (1980) "Cytogenic studies on Abelson-virus-induced mouse leukemias," Int. J. Cancer 25, 805-811.
35. Levan, A. (1956) "Chromosomes in cancer tissue," Ann. N. Y. Acad.
Sci. 63, 774-792.
36. Duesberg, P. H., Bister, K. & Moscovici, C. (1980) "Genetic structure
of avian myeloblastosis virus, released from transformed myeloblasts
as a defective virus particle," Proc. Natl. Acad. Sci. USA 77,
5120-5124.
37. Mellon, P., Pawson, A., Bister, K., Martin, G. S. & Duesberg, P. H.
(1978) "Specific RNA sequences and gene products of MC29 avian
acute leukemia virus," Proc. Natl. Acad. Sci. USA 75, 5874-5878.
38. Lee, W.-H., Bister, K., Pawson, A., Robins, T., Moscovici, C. &
Duesberg, P. H. (1980) "Fujinami sarcoma virus: An avian RNA tumor
virus with a unique transforming gene," Proc. Natl. Acad. Sci. USA
77, 2018-2022.
39. Cichutek, K. & Duesberg, P. H. (1986) "Harvey ras genes transform
without mutant codons, apparently activated by truncation of a 5' exon
(exon -1)," Proc. Natl. Acad. Sci. USA 83, 2340-2344.
40. Kan, N. C., Flordellis, C. S., Mark, G. E., Duesberg, P. H. & Papas,
T. S. (1984) "Nucleotide sequence of avian carcinoma virus MH2: Two
potential onc genes, one related to avian virus MC29 and the other
related to murine sarcoma virus 3611," Proc. Natl. Acad. Sci. USA 81,
3000-3004.
41. Zhou, R.-P., Kan, N., Papas, T. & Duesberg, P. (1985) "Mutagenesis
of avian carcinoma virus MH2: Only one of two potential transforming
genes (5gag-myc) transforms fibroblasts," Proc. Natl. Acad. Sci. USA
82, 6389-6393.
42. Bentley, D. L. & Groudine, M. (1986) "Novel promoter upstream of
the human c-myc gene and regulation of c-myc expression in B-cell
lymphomas," Mol. Cell. Biol. 6, 3481-3489.
43. Feinberg, A. P., Vogelstein, M. J., Droller, S., Baylin, B. & Nelkin,
B. D. (1983) "Mutation affecting the 12th amino acid of the c-Ha-ras
oncogene product occurs infrequently in human cancer," Science 220,
1175-1177.
44. Fujita, J., Srivastava, S., Kraus, M., Rhim, J. S., Tronick, S. R. &
Aaronson, S. A. (1985) "Frequency of molecular alterations affecting
ras protooncogenes in human urinary tract tumors," Proc. Natl. Acad.
Sci. USA 82, 3849-3853.
45. Milici, A., Blick, M., Murphy, E. & Gutterman, J. U. (1986) "c-K-ras
codon 12 GGT-CGT point mutation an infrequent event in human lung
cancer," Biochem. Biophys. Res. Commun. 140, 699-705.
46. Lowy, D. R. & Willumsen, B. W. (1986) "The ras gene family,"
Cancer Surv. 5, 275-289.
47. Marshall, C. (1985) "Human oncogenes," in RNA Tumor Viruses:
Molecular Biology of Tumor Viruses, eds. Weiss, R., Teich, N.,
Varmus, H. & Coffin, J. (Cold Spring Harbor Laboratory, Cold Spring
Harbor, NY), pp. 487-558.
48. Barbacid, M. (1986) "Mutagens, oncogenes and cancer," Trends
Genet. 2, 188-192.
49. Needleman, S. W., Kraus, M. H., Srivastava, S. K., Levine, P. H. &
2124
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
Biochemistry: Duesberg
Aaronson, S. A. (1986) "High frequency of N-ras activation in acute
myelogenous leukemia," Blood 67, 753-757.
Hastings, R. J. & Franks, L. M. (1981) "Chromosome pattern, growth
in agar and tumorigenicity in nude mice of four human bladder
carcinoma cell lines," Int. J. Cancer 27, 15-21.
Wabl, M., Burrows, P. D., von Gabain, A. & Steinberg, A. (1984)
"Hypermutation at the immunoglobulin heavy chain locus in a pre-Bcell line," Proc. Natl. Acad. Sci. USA 82, 479-482.
Drake, J. W. (1969) "Comparative rates of spontaneous mutation,"
Nature (London) 221, 1132.
Sharkey, F. E. & Fogh, J. (1984) "Considerations in the use of nude
mice for cancer research," Cancer Metastasis Rev. 3, 341-360.
Kinlen, L. J. (1982) "Immunosuppressive therapy and cancer," Cancer Surv. 1, 565-583.
Sager, R., Tanaka, K., Lau, C. C., Ebina, Y. & Anisowicz, A. (1983)
"Resistance of human cells to tumorigenesis induced by cloned transforming genes," Proc. Natl. Acad. Sci. USA 80, 7601-7605.
Land, H., Parada, L. F. & Weinberg, R. A. (1983) "Tumorigenic
conversion of primary embryo fibroblasts requires at least two cooperating oncogenes," Nature (London) 304, 596-602.
Land, H., Parada, L. F. & Weinberg, R. A. (1983) "Cellular oncogenes
and multistep carcinogenesis," Science 222, 771-778.
Newbold, R. F. & Overell, R. W. (1983) "Fibroblast immortality is a
prerequisite for transformation by EJ c-Ha-ras oncogene," Nature
(London) 304, 648-651.
Boone, C. W. (1975) "Malignant hemangioendotheliomas produced by
subcutaneous inoculation of BALB/3T3 cells attached to glass beads,"
Science 188, 68-70.
Littlefield, J. W. (1982) "NIH/3T3 cell line," Science 218, 214-216.
Greig, R. G., Koestler, T. P., Trayner, D. L., Corwin, S. P., Miles, L.,
Kline, T., Sweet, R., Yokoyama, S. & Poste, G. (1985) "Tumorigenic
and metastatic properties of 'normal' and ras-transfected NIH/3T3
cells," Proc. Natl. Acad. Sci. USA 82, 3698-3701.
Rubin, H., Chu, B. M. & Arnstein, P. (1983) "Heritable variations in
growth potential and morphology within a clone of Balb/3T3 cells and
their relation to tumor formation," J. Natl. Cancer Inst. 71, 365-373.
Stenman, G., Delorme, E. O., Lau, C. C. & Sager, R. (1987) "Transfection with plasmid pSV2gptEJ induces chromosome rearrangements
in CHEF cells," Proc. NatI. Acad. Sci. USA 84, 184-188.
Reynolds, S. H., Stowers, S. J., Maronpot, R. R., Anderson, M. W. &
Aaronson, S. A. (1986) "Detection and identification of activated
oncogenes in spontaneously occurring benign and malignant hepatocellular tumors of the B6C3F1 mouse," Proc. Natl. Acad. Sci. USA 83,
33-37.
Balmain, A., Ramsden, M., Bowden, G. T. & Smith, J. (1984) "Activation of the mouse cellular Harvey-ras gene in chemically induced
benign skin papillomas," Nature (London) 307, 658-660.
Balmain, A. & Pragnell, I. B. (1983) "Mouse skin carcinomas induced
in vivo by chemical carcinogens have a transforming Harvey-ras
oncogene," Nature (London) 304, 596-602.
Klein, G. & Klein, E. (1984) "Oncogene activation and tumor progression," Carcinogenesis 5, 429-435.
Balmain, A. (1985) "Transforming ras oncogenes and multistage
carcinogenesis," Br. J. Cancer 51, 1-7.
Bums, F. J., Vanderlaan, M., Snyder, E. & Albert, R. E. (1978)
"Induction and progression kinetics of mouse skin papillomas," in
Slaga, T. J., Sivac, A. & Boutwell, R. K., eds., Carcinogenesis, Vol. 2:
Mechanisms of Tumor Promotion and Cocarcinogenesis (Raven, New
York), pp. 91-96.
Albino, A. P., Le Strange, A. I., Oliff, M. I., Furth, M. E. & Old, L. J.
(1984) "Transforming ras genes from human melanoma: A manifestation of tumour heterogeneity?" Nature (London) 308, 69-72.
Tainsky, M. A., Cooper, G. S., Giovanella, B. C. & Vande Woude,
G. F. (1984) "An activated ras N gene: Detected in late but not early
passage human teratocarcinoma cells," Science 225, 643-645.
Vousden, K. H. & Marshall, C. J. (1984) "Three different activated ras
genes in mouse tumors: Evidence for oncogene activation during
progression of a mouse lymphoma," EMBO J. 3, 913-917.
Aaronson, S. A. & Weaver, C. A. (1971) "Characterization of murine
sarcoma virus (Kirsten) transformation of mouse and human cells," J.
Gen. Virol. 13, 245-252.
Hoelzer-Pierce, J. & Aaronson, S. A. (1982) "BALB- and Harveymurine sarcoma virus transformation of a novel lymphoid progenitor
cell," J. Exp. Med. 156, 873-887.
Rapp, U. R., Cleveland, J. L., Fredrickson, T. N., Holmes, K. L.,
Morse, H. C., III, Jansen, H. W., Patschinsky, T. & Bister, K. (1985)
"Rapid induction of hemopoietic neoplasms in newborn mice by a
raftmil)/myc recombinant murine retrovirus," J. Virol. 55, 23-33.
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M.,
Alexander, W. S., Cory, S., Palmiter, R. D. & Brinster, R. L. (1985)
"The c-myc oncogene driven by immunoglobulin enhancers induces
lymphoid malignancy in transgenic mice," Nature (London) 318,
533-538.
Proc. Natl. Acad. Sci. USA 84 (1987)
77. Biggar, R. J., Lee, E. C., Nkrumah, F. K. & Whang-Peng, J. (1981)
"Direct cytogenetic studies by needle stick aspiration of Burkitt's
lymphoma in Ghana, West Africa," J. Natl. Cancer Inst. 67, 769-776.
78. Sprent, J. (1977) "Migration and life span of lymphocytes," in B and T
Cells in Immune Recognition, eds. Loor, F. & Roelants, G. E. (Wiley,
New York), pp. 59-82.
79. Stark, G. R. (1986) "DNA amplification in drug resistant cells and in
tumours," Cancer Surv. 5, 1-23.
80. Schimke, R. T., Sherwood, S. W., Hill, A. B. & Johnston, R. N.
(1986) "Overreplication and recombination of DNA in higher eukaryotes: Potential consequences and biological implications," Proc. Natl.
Acad. Sci. USA 83, 2157-2161.
81. Heisterkamp, N., Stam, K., Groffen, J., De Klein, A. & Grosveld, G.
(1985) "Structural organization of the bcr gene and its role in the Ph'
translocation," Nature (London) 315, 758-761.
82. Kraemer, P. M., Ray, F. A., Brothman, A. R., Bartholdi, M. F. &
Cram, L. S. (1986) "Spontaneous immortalization rate of cultured
Chinese hamster cells," J. Natl. Cancer Inst. 76, 703-709.
83. Ray, F. A., Bartholdi, M. F., Kraemer, P. M. & Cram, L. S. (1986)
"Spontaneous in vitro neoplastic evolution: Recurrent chromosome
changes of newly immortalized Chinese hamster cells," Cancer Genet.
Cytogenet. 21, 35-51.
84. Terzi, M. & Hawkins, T. S. C. (1975) "Chromosomal variation and the
establishment of somatic cell lines in vitro," Nature (London) 253,
361-362.
85. Harnden, D. G., Benn, P. A., Oxford, J. M., Taylor, A. M. R. &
Webb, T. P. (1976) "Cytogenetically marked clones in human fibroblasts cultured from normal subjects," Somat. Cell Genet. 2, 55-62.
86. Martin, G. M., Smith, A. C., Ketterer, D. J., Ogburn, C. E. &
Disteche, C. M. (1985) "Increased chromosomal aberrations in first
metaphases of cells isolated from the kidneys of aged mice," Israel J.
Med. Sci. 21, 296-301.
87. Hook, E. B. (1985) "The impact of aneuploidy upon public health:
Mortality and morbidity associated with human chromosome abnormalities," in Aneuploidy: Etiology and Mechanisms, eds. Dellarco, V. L.,
Voytek, P. E., & Hollaender, A. (Plenum, New York), pp. 7-33.
88. Diamond, A., Cooper, G. M., Ritz, J. & Lane, M.-A. (1983) "Identification and molecular cloning of the human B-lym transforming gene
activated in Burkitt's lymphomas," Nature (London) 305, 112-116.
89. Varmus, H. (1984) "The molecular genetics of cellular oncogenes,"
Annu. Rev. Genet. 18, 553-612.
90. Duesberg, P. H., Bister, K. & Vogt, P. K. (1977) "The RNA of avian
acute leukemia virus MC29," Proc. Natl. Acad. Sci. USA 74,
4320-4324.
91. Wang, L.-H., Duesberg, P. H., Beemon, K. & Vogt, P. K. (1975)
"Mapping RNase T,-resistant oligonucleotides of avian tumor virus
RNAs: Sarcoma-specific oligonucleotides are near the poly(A) end and
oligonucleotides common to sarcoma and transformation-defective
viruses are at the poly(A) end," J. Virol. 16, 1051-1070.
92. Wang, L.-H. (1978) "The gene order of avian RNA tumor viruses
derived from biochemical analyses of deletion mutants and viral recombinants," Annu. Rev. Microbiol. 32, 561-592.
93. Hayflick, J., Seeburg, P. H., Ohlsson, R., Pfeifer-Ohlsson, S., Watson,
D., Papas, T. & Duesberg, P. H. (1985) "Nucleotide sequence of two
overlapping myc-related genes in avian carcinoma virus OK10 and their
relation to the myc genes of other viruses and the cell," Proc. Natl.
Acad. Sci. USA 82, 2718-2722.
94. Duesberg, P., Vogt, P. K., Beemon, K. & Lai, M. (1974) "Avian RNA
tumor viruses: Mechanism of recombination and complexity of the
genome," Cold Spring Harbor Symp. Quant. Biol. 39, 847-857.
95. Nunn, M. F., Seeburg, P. H., Moscovici, C. & Duesberg, P. H. (1983)
"Tripartite structure of the avian erythroblastosis virus E26 transforming gene," Nature (London) 306, 391-395.
96. Pfaff, S. L., Zhou, R.-P., Young, J. C., Hayflick, J. & Duesberg, P. H.
(1985) "Defining the borders of the chicken proto-fps gene, a precursor
of Fujinami sarcoma virus," Virology 146, 307-314.
97. van der Hoorn, A. & Neupert, B. (1986) "The repressor sequence
upstream of c-mos acts neither as polyadenylation site nor as transcription termination region," Nucleic Acids Res. 14, 8771-8782.
98. Ikawa, S., Hagino-Yamagishi, K., Kawai, S., Yamamoto, T. &
Toyoshima, K. (1986) "Activation of the cellular src gene by transducing retrovirus," Mol. Cell. Biol. 6, 2420-2428.
99. Naharro, G., Robbins, K. C. & Reddy, E. P. (1984) "Gene product of
v-fgr onc: Hybrid protein containing a portion of actin and a tyrosinespecific protein kinase," Science 223, 63-66.
100. Boveri, T. (1914) Zur Frage der Entstehung maligner Tumoren
(Fischer, Jena, G.D.R.).
101. Rous, P. (1967) "The challenge to man of the neoplastic cell," Science
157, 24-28.
102. Cairns, J. (1978) Cancer, science and society (Freeman, San
Francisco).
103. Bishop, J. M. (1982) "Oncogenes,"
Scientific American 246 (3), 80-90.